TCM
TCG Crossover Management Portfolio holdings
AUM
$876M
This Quarter Return
-11.22%
1 Year Return
+23.66%
3 Year Return
+996.72%
5 Year Return
–
10 Year Return
–
AUM
$960M
AUM Growth
+$960M
(-24%)
Cap. Flow
-$76.2M
Cap. Flow
% of AUM
-7.94%
Top 10 Holdings %
Top 10 Hldgs %
64.7%
Holding
35
New
2
Increased
6
Reduced
4
Closed
3
Top Buys
| 1 |
ABVX
Abivax
ABVX
|
$65.5M |
| 2 |
Disc Medicine
IRON
|
$21.9M |
| 3 |
Savara
SVRA
|
$9.52M |
| 4 |
EyePoint Pharmaceuticals
EYPT
|
$8.02M |
| 5 |
CNTA
Centessa Pharmaceuticals
CNTA
|
$7.68M |
Top Sells
| 1 |
INBX
Inhibrx, Inc. Common Stock
INBX
|
$61.2M |
| 2 |
Geron
GERN
|
$57.4M |
| 3 |
Structure Therapeutics
GPCR
|
$35.5M |
| 4 |
Astria Therapeutics
ATXS
|
$22.9M |
| 5 |
KalVista Pharmaceuticals
KALV
|
$13.8M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
C4 Therapeutics
CCCC
$185M
| $5.9M | 0.61% |
1,276,574
| – | – |
|
27
Nektar Therapeutics
NKTR
$568M
| $4.96M | 0.52% |
4,000,000
| – | – |
|
|
JBIO
28
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $3.72M | 0.39% |
2,240,809
+39,535
| +2% | +$65.6K |
|
29
AN2 Therapeutics
ANTX
$30.1M
| $3.34M | 0.35% |
1,555,118
| – | – |
|
30
Kodiak Sciences
KOD
$478M
| $2.11M | 0.22% |
899,999
| – | – |
|
31
Ventyx Biosciences
VTYX
$171M
| $730K | 0.08% |
316,195
-499,529
| -61% | -$1.15M |
|
32
Cabaletta Bio
CABA
$133M
| $649K | 0.07% |
86,795
| – | – |
|
|
33
Geron
GERN
$893M
| – | – |
-17,391,639
| Closed | -$57.4M |
|
|
34
KalVista Pharmaceuticals
KALV
$678M
| – | – |
-1,163,356
| Closed | -$13.8M |
|
|
INBX
35
DELISTED
Inhibrx, Inc. Common Stock
INBX
| – | – |
-1,750,387
| Closed | -$61.2M |
|